France: ArchiMed takes lead in recapitalising North American CDMO

Paris-based PE healthcare specialist, ArchiMed, through its MED III fund, is lead investor in an alliance recapitalizing Canada-based Corealis Pharma, a leading CDMO for pharmaceutical oral solid dosage formulation and clinical supply manufacturing. The financing will accelerate growth, including the build out of laboratories and Good Manufacturing Practices-compliant facilities. ArchiMed and fellow investor, the Caisse…

You must be a HMI Subscriber to view this content.

Subscribe Now »